MedTrace Logo

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

NCT03446547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-04-14

No results posted yet for this study

Summary

This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.

Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months

Conditions

  • NSCLC, Stage I

Interventions

DRUG

Durvalumab

durvalumab 1500 mg i.v. every fourth week for 12 months

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Andreas Hallqvist, PhD · Göteborg University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-04
Primary Completion
2025-10-01
Completion
2025-10-01
FDA Drug
Yes

Countries

  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03446547 on ClinicalTrials.gov